Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Tsutsui, Ko ^a   Kanbayashi, Takashi ^a   Tanaka, Keiko ^b   Boku, Shuken ^c   Ito, Wakako ^a,d   Tokunaga, Jun ^a   Mori, Akane ^a   Hishikawa, Yasuo ^a,e   Shimizu, Tetsuo ^a   Nishino, Seiji ^f  

^a AKITA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Akita Kaiseikai Hospital   (Japan)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; AUTONOMIC DYSFUNCTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENCEPHALITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; NEUROPSYCHIATRY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SLEEP DISORDER; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; CLINICAL ARTICLE; CLINICAL FEATURE; FOLLOW UP; MENTAL DISEASE;

ADOLESCENT; ADULT; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; AUTOANTIBODIES; ENCEPHALITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; PSYCHOTIC DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84860648597     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-37     Document Type: Article

References (42)

1. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005, 58(4):594-604. 10.1002/ana.20614, 2245881, 16178029.
2. Kamei S, Kuzuhara S, Ishihara M, Morita A, Taira N, Togo M, Matsui M, Ogawa M, Hisanaga K, Mizutani T, Kuno S. Nationwide survey of acute juvenile female non-herpetic encephalitis in Japan: relationship to anti-N-methyl-D-aspartate receptor encephalitis. Intern Med 2009, 48(9):673-679. 10.2169/internalmedicine.48.1898, 19420812.
3. Nokura K, Yamamoto H, Okawara Y, Koga H, Osawa H, Sakai K. Reversible limbic encephalitis caused by ovarian teratoma. Acta Neurol Scand 1997, 95:367-373. 10.1111/j.1600-0404.1997.tb00227.x, 9228272.
4. Okamura H, Oomori N, Uchitomi Y. An acutely confused 15-year-old girl. Lancet 1997, 350:488. 10.1016/S0140-6736(97)06208-9, 9274586.
5. Kleinig TJ, Thompson PD, Matar W, Duggins A, Kimber TE, Morris JG, Kneebone CS, Blumbergs PC. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord 2008, 23:1256-1261. 10.1002/mds.22073, 18442127.
6. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25-36. 10.1002/ana.21050, 2430743, 17262855.
7. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011, 231(1-2):86-91.
8. Iizuka T. Clinical features and pathogenesis of anti-NMDA receptor encephalitis. Rinsho Shinkeigaku 2008, 11:920-922. in Japanese.
9. Sansing LH, Tüzün E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007, 3(5):291-296. 1936221, 17479076.
10. Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J, Lammers GJ. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 2004, 62(1):138-140. 10.1212/01.WNL.0000101718.92619.67, 2574537, 14718718.
11. Kanbayashi T, Shimohata T, Nakashima I, Yaguchi H, Yabe I, Nishizawa M, Shimizu T, Nishino S. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009, 66(12):1563-1566. 10.1001/archneurol.2009.264, 20008665.
12. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, Kawashima M, Bayard S, Monaca C, Tiberge M, Filipini D, Tripathy A, Nguyen BH, Kotagal S, Mignot E. Post-H1N1 narcolepsy-cataplexy. Sleep 2010, 33(11):1428-1430. 2954689, 21102981.
13. Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE, Rossi JE, Bien CG. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009, 66(4):458-464. 10.1001/archneurol.2009.5, 19364930.
14. Tsutsui K, Ouchi H, Teshima K, Tokunaga J, Ishiguro H, Takemura F, Mori A, Kanbayashi T, Shimizu T. A case of NMDAR encephalitis initially suspected psychosis. Seisin Igaku 2010, 52(11):1107-1109. in Japanese.
15. Tsutsui K, Tokunaga J, Mori A, Kondo R, Iwaya K, Fushimi S, Okawa S, Sugawara J, Namura I, Kanbayashi T, Shimizu T. A male case of NMDAR encephalitis. Seishinka Chiryogaku 2011, 26(2):235-239. in Japanese.
16. Maeda T, Nagata K, Kondo H, Kanbayashi T. Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level. Sleep Med 2006, 7(8):662. 10.1016/j.sleep.2006.05.017, 17097921.
17. Takahashi Y, Kikuchi Y, Kanbayashi T, Hanazono A, Abe S, Iwaki S, Tsutsui K, Suda H, Maruyama F, Shimizu T. A case with hypocretin (orexin) deficient narcolepsy. Parkinson's disease and severe psychosis was successfully treated by modified electro-convulsive therapy. Akita J Med 2011, 38:81-84.
18. Tsutsui K, Kikuchi Y, Mori A, Mikami M, Kanbayashi T, Shimizu T. Anti-NMDAR encephalitis which takes eight years for diagnosis. Pschiatry 2011, 6:683-686. in Japanese.
19. Suda H, Tsutsui K, Mori A, Hosokawa R, Ishikawa Y, Echizenya M, Kanbayashi T, Shimizu T. A Schizophrenia case who was treated with maintenance modified electric convulsion therapy were indicated NMDA receptor antibody positive. Seishinka Chiryogaku 2011, 26(10):1327-1331.
20. Tanaka K, Nakata M, Matsui M, Sakimura K. Clinical spectrum of anti-NMDA receptor antibody related encephalitis diagnosed by cell-based immunofluorescense detection system. J Neuroimmunol 2010, 228:A181.
21. Zhang Q, Tanaka K, Sun P, Nakata M, Yamamoto R, Sakimura K, Matsui M, Kato N. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 2012, 45(1):610-615. Epub 2011 Oct 8, 10.1016/j.nbd.2011.09.019, 22008231.
22. Lee A, Glick DB, Dinwiddie SH. Electroconvulsive therapy in a pediatric patient with malignant catatonia and paraneoplastic limbic encephalitis. J ECT 2006, 22:267-270.
23. Braakman HM, Moers-Hornikx VM, Arts BM, Hupperts RM, Nicolai J. Pearls & Oy-sters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology 2010, 75(10):e44-e46. 10.1212/WNL.0b013e3181f11dc1, 20819992.
24. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005, 10:40-68. 10.1038/sj.mp.4001558, 15263907.
25. Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 2007, 78:69-108.
26. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 2009, 35:509-527. 10.1093/schbul/sbn176, 2669579, 19155345.
27. Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol Cell Biol 2005, 83:9-17. 10.1111/j.1440-1711.2005.01305.x, 15661036.
28. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, , Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA. Genetic Risk and Outcome in Psychosis (GROUP) Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747. 3077530, 19571808, Genetic Risk and Outcome in Psychosis (GROUP).
29. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098. 10.1016/S1474-4422(08)70224-2, 2607118, 18851928.
30. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J. Source: Potassium channel antibody- associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127:701-712.
31. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133(Pt 6):1655-1667. 2877907, 20511282.
32. Parthasarathi UD, Harrower T, Tempest M, Hodges JR, Walsh C, McKenna PJ, Fletcher PC. Source: Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report. Br J Psychiatry 2006, 189:182-183.
33. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011, 258(4):686-688. 10.1007/s00415-010-5788-9, 3065649, 20972895.
34. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10(1):63-74. 10.1016/S1474-4422(10)70253-2, 3158385, 21163445.
35. Seki M, Suzuki S, Iizuka T, Shimizu T, Nihei Y, Suzuki N, Dalmau J. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 2008, 79:324-326. 10.1136/jnnp.2007.136473, 2574536, 18032452.
36. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, Dalmau J. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008, 70:504-511. 10.1212/01.wnl.0000278388.90370.c3, 2586938, 17898324.
37. Shindo A, Kagawa K, Ii Y, Sasaki R, Kokubo Y, Kuzuhara S. Anti-N-methyl-D-aspartate receptor-related grave but reversible encephalitis with ovarian teratoma in 2 Japanese women presenting with excellent recovery without tumor resection. Eur Neurol 2009, 61:50-51. 10.1159/000175122, 19033688.
38. Dale RC, Irani SR, Brilot F, Pillai S, Webster R, Gill D, Lang B, Vincent A. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009, 66:704-709.
39. Mitsuda H, Fukuda T. Biological Mechanisms of Schizophrenia and Schizophrenia-like Psychoses 1974, Igaku Shoin Company Ltd., Tokyo.
40. Montgomery JH, Vasu D. The use of electroconvulsive therapy in atypical psychotic presentations: a case review. Psychiatry (Edgmont) 2007, 4(10):30-39.
41. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009, 66:11-18. 10.1002/ana.21756, 2826225, 19670433.
42. Watkins CJ, Pei Q, Newberry NR. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Mol Brain Res 1998, 61:108-113. 10.1016/S0169-328X(98)00211-3, 9795172.